New & Noteworthy

Pharm Exec's Emerging Pharma Leaders 2015 — Nominate Now

It's time for you to tell us who you think should receive Pharm Exec's 2014 Emerging Pharma Leadership Award. Read more for details of how to nominate a colleague — or yourself.

CES15: What Happened in Vegas

Bill Drummy presents the highlights (what he will admit to, anyway) from this month's International Consumer Electronics Show in Las Vegas.

FDA Encourages Supplements for Oncology Drug

FDA's Office of Hematology and Oncology Products (OHOP) is testing a treamlined review process that could be much faster and less costly for certain therapies. Jill Wechsler reports.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Beyond the Blame Game: How Pharma is Learning to Collaborate

Pharma stakeholders are putting more energy into building partnerships that can deliver high-quality care to the greatest number of people, writes Novo Nordisk’s Jesper Høiland.

Europe

Former Roche CEO Joins Portugal's BIAL

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

England's Cancer Drug Fund Conundrum

Leela Barham looks at some of the questions that still need to be asked of England's controversial Cancer Drug Fund.

Global

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Got Ideas? Go North!

The Canadian R&D industry, which boasts a rich history of drug innovation, celebrates a series of anniversaries.

Pharma in Cuba: An Untapped Market?

If you’re like us at PharmExec, you’ve been reading the news of potentially thawing US/Cuban relations, and you’re wondering, how long before the flag of Cuba graces the Hall of nations at BIO International Convention?

Country Report: Algeria

Once considered a healthcare backwater, Algeria's expanding pharmaceuticals market is taking the African continent by storm.

Ireland's Celtic Tiger: Back on the Hunt

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

Strategy

Supply Chain Analytics: Pharma’s Next Big Bet

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.

Sanofi’s Big Bet on Integrated Patient Care

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

Pharma Manufacturing Outsourcing: 2014 in Review

Eric Langer assesses the findings of BioPlan’s 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.

Express Scripts to Center Stage

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

Blogs

House "Cures" Proposal Faces Tough Road Ahead

The "discussion draft" for legislation to speed "21st Century Cures" to patients emerged very quietly on Capitol Hill this week. Jill Wechsler reports.

FDA Encourages Supplements for Oncology Drug

FDA's Office of Hematology and Oncology Products (OHOP) is testing a treamlined review process that could be much faster and less costly for certain therapies. Jill Wechsler reports.

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

2015: Blockbuster Year for M&A in Asia

The healthcare landscape in Asia-Pacific is expected to continue grow strongly in 2015, according to a report by Frost & Sullivan.

News Update

European Hantavirus Diagnostics Market Outperforms US

The European Hantavirus diagnostics market is growing at a CAGR of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent.

GSK Announces Nominations Committee Board Changes

Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, effective today (January 27).

Former Roche CEO Joins Portugal's BIAL

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

$5 Million Payout for Viehbacher

Sanofi has agreed to pay its former CEO Chris Viehbacher a total of Euro 4.44 million ($5.06 million).

Colorectal Cancer Market to Grow Despite Avastin Patent Expiration

The value of the Colorectal Cancer (CRC) therapeutics market will increase from $8.3 billion in 2013 to $9.4 billion by 2020, according to a report from GBI Research.

Regulatory

House "Cures" Proposal Faces Tough Road Ahead

The "discussion draft" for legislation to speed "21st Century Cures" to patients emerged very quietly on Capitol Hill this week. Jill Wechsler reports.

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

Europe’s New Competition Commissioner: What Does it Mean for Pharma?

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Politics & Prices Dominate 2015 Agenda

Transparency, quality, collaboration key to filling pipelines, gaining reimbursement.

Sales & Marketing

What's Wrong with the Annual Sales Kickoff: And How to Fix it

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate. By Duncan Lennox.

Digital's Place in the Pharma Marketing Mix

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

OTC Drug Advertising: Alfred Hitchcock Style

The legendary director's on-screen attitude to his TV show's sponsor, Bristol-Myers, caused some consternation—until the drugmaker saw the results.

Social Media and the In-House Counsel

What is and what should be keeping you up at night.

R&D

Pharmacies — A New Patient Education Opportunity

Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.

Open Innovation in Pharma: Defining the Dialogue

There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?